礼来（Eli Lilly）股价在盘前交易中大涨11.99%，引发市场广泛关注。这一显著涨幅源于公司宣布其口服减肥药Orforglipron在3期临床试验中达到主要终点。
根据礼来公司的声明，Orforglipron是第一个口服小分子胰高血糖素样肽-1（GLP-1）受体激动剂，无需饮食和水限制。在最高剂量下，参与者平均减重16磅（约7.3公斤）。这一结果不仅展示了药物的有效性，还凸显了其在使用便利性方面的优势。
礼来公司表示，对于在全球推出Orforglipron而不受供应限制的能力充满信心。这一新药有望进一步推动礼来减少2型糖尿病等慢性病的使命。分析师普遍看好礼来的发展前景，认为该公司在快速增长的减肥药市场中占据有利地位。随着肥胖症和相关健康问题的日益普遍，市场对有效且便捷的减肥解决方案的需求持续增长，这可能为礼来带来可观的收入增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.